BAY 43-9006: preclinical data.

Abstract

The drug design and discovery efforts described in the previous section led to the development of a novel, small molecule Raf-1 kinase inhibitor, BAY 43-9006, which belongs to a class that can be broadly described as bis-aryl ureas (Figure 1). BAY 43-9006 was identified during a large medicinal chemistry optimization program, and this compound was selected for further pharmacological characterization based on its potent inhibition of Raf-1 (IC(50) 12 nM) and its favorable kinase selectivity profile. In vitro and in vivo experiments were designed to demonstrate effective blockade of the Raf/MEK/ERK signaling pathway in tumor cells and for anti tumor efficacy in human xenograft models.

0200400600'04'06'08'10'12'14'16
Citations per Year

3,561 Citations

Semantic Scholar estimates that this publication has 3,561 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wilhelm2002BAY4P, title={BAY 43-9006: preclinical data.}, author={Scott M. Wilhelm and Du-Shieng Chien}, journal={Current pharmaceutical design}, year={2002}, volume={8 25}, pages={2255-7} }